KIZ

The KIZ gene provides instructions for a protein called kizuna, which localizes to the centrosome — a structure inside cells — and strengthens the region around it before cells divide. Researchers have shown that kizuna also sits at the basal body of the cilium, a tiny antenna-like projection. Because photoreceptors (the light-sensing cells of the retina) rely on a specialized cilium to work, KIZ is considered a ciliary gene, and conditions caused by ciliary problems are sometimes called ciliopathies. KIZ is also known by the alias RP69. Disease linked to KIZ follows an autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.) pattern, meaning a person typically has disease-associated changes in both copies of the gene (one inherited from each parent) before retinal symptoms appear.

In the reports available to RP Hope, KIZ-associated disease has most often been described as a rod-cone dystrophy (retinitis pigmentosa): rod photoreceptors, which handle night and side vision, are affected earlier, so people described night blindness and shrinking peripheral vision over time. One long-term imaging study described KIZ-associated disease as an early-onset, severe rod-cone dystrophy with progressive loss of the retinal pigment epithelium and photoreceptors, and it measured gradual annual declines in visual acuity, flicker responses, and the preserved central retinal band. In contrast, a report comparing a large group of KIZ patients found their disease was less severe than that caused by some other RP genes, and a separate single-patient report described relatively mild disease with cone responses still present into the person's 60s. Some people have shown a mainly macular (central) pattern with fluid-filled cysts in the macula (cystoid macular changes). A few reports describe carbonic anhydrase inhibitor eye drops (dorzolamide) being used to reduce these macular cysts, with improvement noted in individual patients. A case series also linked KIZ to a rare complication called Coats-like vasculopathy, an abnormal-blood-vessel change that can cause additional vision loss. These reports show that presentation and severity can vary from person to person.

It is well established from human genetic studies that biallelic (two-copy) changes in KIZ cause autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.) rod-cone dystrophy. The gene was first identified as a cause in 2014 through whole-exome sequencing of families with this condition, and the same nonsense variant c.226C>T (p.Arg76*) has been reported repeatedly since. A later study of 31 patients confirmed that c.226C>T is a founder mutation among people of Jewish (Ashkenazi) descent and that KIZ disease was generally milder than disease from two comparison genes. KIZ appears as a confirmed cause in more than one person within broader clinical sequencing cohorts, supporting its inclusion in diagnostic gene panels for inherited retinal disease. Researchers have also confirmed that KIZ is expressed in the retina and localizes to the base of the cilium, consistent with its role in photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) function.

Much about KIZ-associated disease remains uncertain because the reports are small. Descriptions range from early-onset severe disease to relatively mild disease with preserved cone responses into later life, and the reasons for this variation are not fully explained. How quickly vision changes for any individual cannot be predicted from these reports. The link between KIZ and systemic (whole-body) features is not clearly defined; because KIZ is a ciliary gene, some authors advise checking for other body-system findings, but the available records do not establish a consistent syndromic picture. The connection to Coats-like vasculopathy rests on a small case series and literature review. One study also noted that a common KIZ variant disrupts RNA splicing in a way that could make certain RNA-based therapies less effective, but this was laboratory and expression work, not a treatment tested in people.

RP Hope's reviewed records do not currently identify a gene-specific approved treatment for KIZ-associated retinal disease. In some individual reports, carbonic anhydrase inhibitor eye drops (dorzolamide) were used to reduce fluid-filled macular cysts, with improvement described in single patients; this addresses a specific complication rather than the underlying condition, and any use would be a clinical decision made with an eye care team. On the research side, laboratory work has explored RNA-editing strategies aimed at nonsense mutations, including a KIZ variant, but this remains preclinical (definition: Research done in cells or animals, before a treatment is considered ready to be studied in people.) (cell and yeast-based) work and is not an available therapy. One study also cautioned that a common KIZ splicing effect could limit the efficacy of some RNA-based approaches. These are early-stage findings and not treatments people can receive today.

• KIZ identified as a cause of recessive rod-cone dystrophy

  Human genetic study combined with laboratory and mouse expression work.

  What was found:

  They identified disease-causing KIZ variants, including the recurrent c.226C>T (p.Arg76*) nonsense change, and confirmed that KIZ is expressed in the retina and sits at the base of the cilium in cells.

  Why it matters:

  This established KIZ as a ciliary gene that causes autosomal recessive rod-cone dystrophy and supports its inclusion in genetic testing panels.

  Limitation: Only a small number of affected individuals carried KIZ variants, and the biological work in mice describes gene activity rather than any treatment.

• Larger patient group and a splicing mechanism

  Human clinical and genetic study with laboratory RNA analysis.

  What was found:

  Most patients carried the c.226C>T founder mutation common among people of Ashkenazi Jewish descent; their disease was less severe than that of two comparison genes, and the variant was found to disrupt normal RNA splicing.

  Why it matters:

  It gives a clearer picture of how KIZ disease presents in a larger group and cautions that some RNA-based therapies might be less effective because of the splicing effect.

  Limitation: The cohort is dominated by one founder mutation, so findings may not represent all KIZ variants or populations.

• Preclinical RNA-editing approach including KIZ

  Preclinical laboratory (cell and yeast) research.

  What was found:

  They identified guide RNAs able to edit target sequences and proposed the approach as a basis for future gene-therapy research.

  Why it matters:

  It illustrates an early research direction that could eventually target certain KIZ mutations.

  Limitation: This is early experimental work, not a therapy available to patients, and its usefulness for KIZ may be limited by the gene's splicing behavior noted elsewhere.

• Long-term progression measured with imaging

  Observational human clinical study (small case series).

  What was found:

  Researchers observed progressive loss of the retinal pigment epithelium and photoreceptors, with measurable yearly declines, and described KIZ-associated disease as an early-onset, severe rod-cone dystrophy.

  Why it matters:

  It provides quantitative natural-history data that can inform monitoring and future studies.

  Limitation: Only four patients were studied, and this severe characterization contrasts with milder cases in other reports.

• Macular-predominant phenotype and cyst response to eye drops

  Single case report.

  What was found:

  She had macular cysts and outer retinal atrophy; treatment with dorzolamide eye drops was associated with improvement in the macular cysts.

  Why it matters:

  It shows KIZ disease can look mainly macular and that a specific complication (cystoid macular changes) may respond to carbonic anhydrase inhibitor drops in some individuals.

  Limitation: A single patient cannot establish how often this pattern or treatment response occurs; it is not a gene-specific cure.

Family members may have questions about their own risk because KIZ disease is inherited in an autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.) way; a genetic counselor can explain carrier testing and what results would mean. For day-to-day support, a helpful starting point is asking the person what kind of assistance they actually prefer rather than assuming, since vision and needs vary widely among people with KIZ-associated disease. Low-vision rehabilitation, accessible technology, and support with transportation or workplace and school accommodations can preserve independence. Emotional and community support matters too; RP Hope's Patient and Family Stories share first-person experiences of navigating a diagnosis. RP Hope's My RP Pathway can guide families to relevant resources.

• What do my specific KIZ variants mean, and are they considered pathogenic, likely pathogenic, or uncertain?
• Based on my exam and imaging, does my retinal pattern look more like an early-onset severe or a milder form of KIZ-associated disease?
• Should I be monitored for macular cysts or Coats-like vessel changes, and how often?
• Given that KIZ is a ciliary gene, is any evaluation for other body-system findings appropriate in my case?
• What does autosomal recessive inheritance mean for my children, siblings, or other relatives?
• Which low-vision, imaging, or specialist follow-up would you recommend for me now?

A genetic result naming KIZ is something to review with a retinal specialist and a genetic counselor, who can confirm what the specific variants mean and place them in the context of a full eye examination. Genetic counseling can also help explain the autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.) inheritance pattern and what it may mean for relatives. Because some reports describe macular cysts and a rare vessel complication, ongoing monitoring with retinal imaging may be discussed with an eye care team. RP Hope's Genetic Testing resource explains what testing involves and what to ask, and My RP Pathway offers a guided tour of support at any stage.